Review
Biochemistry & Molecular Biology
Jerremy Weerts, Sanne G. J. Mourmans, Arantxa Barandiaran Aizpurua, Blanche L. M. Schroen, Christian Knackstedt, Etto Eringa, Alfons J. H. M. Houben, Vanessa P. M. van Empel
Summary: Heart failure with preserved ejection fraction (HFpEF) is a disease with increasing incidence and no effective treatment. Coronary microvascular dysfunction plays a key role in the pathophysiology of HFpEF, possibly due to a low-grade pro-inflammatory state caused by systemic comorbidities. The presence or absence of peripheral microvascular dysfunction in HFpEF may reflect whether it is predominantly a cardiac or a systemic disease.
Article
Medicine, Research & Experimental
Mandy Otto, Laura Brabenec, Melanie Mueller, Sebastian Kintrup, Katharina E. M. Hellenthal, Richard Holtmeier, Sophie Charlotte Steinbuch, Ole Sonken Karsten, Heorhii Pryvalov, Jan Rossaint, Eric R. Gross, Nana-Maria Wagner
Summary: The study suggests that 12-HETE may serve as a biomarker for endothelial dysfunction and HFpEF in patients with type 2 diabetes. Antagonizing 12-HETE is a potent way to control the development and progression of HFpEF in type 2 diabetes by preserving vascular function.
Article
Cardiac & Cardiovascular Systems
Yogesh N. Reddy, Barry A. Borlaug, Bernard J. Gersh
Summary: Atrial fibrillation is the most common arrhythmia in heart failure patients and can be both the cause and consequence of clinical heart failure. Some patients may benefit from maintaining sinus rhythm with catheter ablation. There is a close relationship between atrial fibrillation, left atrial myopathy, mitral regurgitation, and heart failure with preserved ejection fraction, with potential clinical benefits to catheter ablation therapy. Treatment of atrial fibrillation also requires consideration of the degree of atrial myopathy and chronicity of atrial fibrillation.
Letter
Medicine, General & Internal
Elric Zweck, Ralf Westenfeld, Bjorn Redfors, Elmir Omerovic, Robin A. P. Weir, Domenico Gabrielli, Fabrizio Oliva, Giuseppe Zuccala, Scott D. Solomon, Muthiah Vaduganathan, John J. V. McMurray
Summary: Solomon et al. report on the DELIVER trial, which showed that dapagliflozin reduced risks of heart failure-related outcomes in patients with a mildly reduced or preserved left ventricular ejection fraction. These findings are expected to influence guidelines and clinical practice. The trial also confirmed dapagliflozin's efficacy in patients with a left ventricular ejection fraction of 60% or above.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Review
Medicine, Research & Experimental
Min Zhang, Hongyang Shu, Chen Chen, Zuowen He, Zhou Zhou, Dao Wen Wang
Summary: Heart failure with preserved ejection fraction (HFpEF) has a negative impact on quality of life, requires significant medical resources, and has a high mortality rate. Currently, there is a lack of effective therapy for HFpEF due to limited knowledge of its mechanism. Epoxyeicosatrienoic acids (EETs) are endogenous cardioprotective factors that have inhibitory effects on the fundamental mechanisms of HFpEF, such as inflammation, endothelial dysfunction, cardiac remodeling, and fibrosis. Therefore, exploring the potential of EETs as a therapeutic target for HFpEF is crucial.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Letter
Medicine, General & Internal
Debdatta Bhattacharyya, Ayan Kar, Saurabh Dhumale, Filippos K. Triposkiadis, Andrew Xanthopoulos, Efstathios K. Iliodromitis, James Amato, Hiddo J. L. Heerspink, Lesley Inker, Tom Greene, Stefan D. Anker, Javed Butler, Milton Packer
Summary: In patients with heart failure and preserved ejection fraction, Empagliflozin reduced the incidence of primary outcome events compared to other drugs, but had higher rates of cardiovascular death, death from any cause, and hospitalization for heart failure compared to spironolactone.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Cardiac & Cardiovascular Systems
Mingming Yang, Toru Kondo, Jawad H. Butt, William T. Abraham, Inder S. Anand, Akshay S. Desai, Lars Kober, Milton Packer, Marc A. Pfeffer, Jean L. Rouleau, Marc S. Sabatine, Scott D. Solomon, Karl Swedberg, Michael R. Zile, Pardeep S. Jhund, John J. McMurray
Summary: Patients with heart failure who have a history of stroke are at a high risk of subsequent cardiovascular events, regardless of ejection fraction. This study investigated the prevalence of stroke history in patients with heart failure and found that they had more vascular comorbidity and worse heart failure compared to those without stroke history. Targeting underutilization of guideline-recommended treatments might improve outcomes in this high-risk population.
EUROPEAN HEART JOURNAL
(2023)
Review
Pharmacology & Pharmacy
Alexandrina Campos-Martins, Bruno Braganca, Paulo Correia-de-Sa, Ana Patricia Fontes-Sousa
Summary: HFpEF represents half of cardiac failure events in developed countries and is one of the greatest unmet clinical necessities worldwide. Adenosine, by activating plasma membrane-bound P1 receptors, exerts cardioprotective, neuromodulatory, and immunosuppressive effects, with proven benefits demonstrated in preclinical animal tests. Tuning adenosine signaling pathways in HFpEF offers therapeutic advantages.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Sebastian Rosch, Karl-Patrik Kresoja, Christian Besler, Karl Fengler, Anne Rebecca Schoeber, Maximilian von Roeder, Christian Luecke, Matthias Gutberlet, Karin Klingel, Holger Thiele, Karl-Philipp Rommel, Philipp Lurz
Summary: In this study, patients with heart failure with preserved ejection fraction (HFpEF) were stratified based on left ventricular ejection fraction (LVEF), resulting in distinct morphologic and pathophysiologic subphenotypes. Patients with LVEF ranging from 50% to 60% demonstrated reduced contractility, impaired ventriculo-arterial coupling, and higher extracellular volume fraction, while patients with LVEF >60% exhibited a hypercontractile state with excessive left ventricular afterload and diminished preload reserve.
Article
Cardiac & Cardiovascular Systems
Ning Ding, Amil M. Shah, Michael J. Blaha, Patricia P. Chang, Wayne D. Rosamond, Kunihiro Matsushita
Summary: This study aimed to evaluate the association between smoking and different phenotypes of heart failure. The results showed a significant association between smoking and the incidence of HFpEF and HFrEF, and smoking cessation significantly reduced the risk of HF.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Jawad H. Butt, Toru Kondo, Pardeep S. Jhund, Josep Comin-Colet, Rudolf A. de Boer, Akshai S. Desai, Adrian F. Hernandez, Silvio E. Inzucchi, Stefan P. Janssens, Mikhail N. Kosiborod, Carolyn S. P. Lam, Anna Maria Langkilde, Daniel Lindholm, Felipe Martinez, Magnus Petersson, Sanjiv J. Shah, Jorge Thierer, Muthiah Vaduganathan, Subodh Verma, Ulrica Wilderang, Brian C. Claggett, Scott D. Solomon, John J. V. McMurray
Summary: This study examined the effects of dapagliflozin in patients with atrial fibrillation (AF) and found that its benefits were consistent across different types of AF.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2022)
Review
Cell Biology
Angela Rocca, Ruud B. van Heeswijk, Jonas Richiardi, Philippe Meyer, Roger Hullin
Summary: Heart failure with preserved left ventricular ejection fraction (HFpEF) is a prevalent form of heart failure, but its pathophysiology is not fully understood and the patient population is heterogeneous. Recent studies using animal models have provided new insights into the cellular pathophysiology of HFpEF, which may lead to the development of new therapeutic targets.
Review
Physiology
Lauriane Cornuault, Paul Rouault, Cecile Duplaa, Thierry Couffinhal, Marie-Ange Renault
Summary: Heart failure with preserved ejection fraction (HFpEF) is a significant unmet need in cardiovascular medicine, with high morbidity and mortality. The pathophysiology of HFpEF is still poorly understood, but there is a unified theory suggesting the role of endothelial dysfunction.
FRONTIERS IN PHYSIOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Xiaoqian Wu, Huan Liu, Alan Brooks, Suowen Xu, Jinque Luo, Rebbeca Steiner, Deanne M. Mickelsen, Christine S. Moravec, Alexis D. Jeffrey, Eric M. Small, Zheng Gen Jin
Summary: The study reveals that reduced endothelial SIRT6 expression is associated with the development of diabetes-related HFpEF, and improving cardiac function by inhibiting endothelial fatty acid uptake. Activation of SIRT6 with medication reduces cardiac lipid accumulation and improves diastolic function.
CIRCULATION RESEARCH
(2022)
Article
Cardiac & Cardiovascular Systems
Barry A. Borlaug, Kavita Sharma, Sanjiv J. Shah, Jennifer E. Ho
Summary: The incidence and prevalence of heart failure with preserved ejection fraction (HFpEF) is increasing due to aging, obesity, sedentariness, and cardiometabolic disorders. Despite recent advances in understanding its pathophysiological effects and introduction of new diagnosis approaches, HFpEF remains under-recognized. This is concerning as effective treatments have been identified. This article provides an in-depth examination of the epidemiology, pathophysiology, diagnosis, and treatment of HFpEF. (J Am Coll Cardiol 2023;81:1810-1834) (c) 2023 by the American College of Cardiology Foundation.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Elisa Dal Canto, Sharon Remmelzwaal, Adriana Johanne van Ballegooijen, M. Louis Handoko, Stephane Heymans, Vanessa van Empel, Walter J. Paulus, Giel Nijpels, Petra Elders, Joline W. J. Beulens
Summary: This study evaluated the diagnostic performance of echocardiographic markers for HFpEF and LVDD, finding that a multivariable model showed the highest diagnostic performance, left atrial strain had reasonable performance, and adding exercise E/e ' improved the sensitivity of HFpEF diagnostic algorithms. Larger, well-designed studies are needed to further evaluate the potential diagnostic role of novel tools in current diagnostic algorithms.
HEART FAILURE REVIEWS
(2022)
Article
Cardiac & Cardiovascular Systems
Massimo F. Piepoli, Marianna Adamo, Andrea Barison, Reinaldo B. Bestetti, Jan Biegus, Michael Boehm, Javed Butler, Jonathan Carapetis, Claudio Ceconi, Ovidiu Chioncel, Andrew Coats, Maria G. Crespo-Leiro, Giovanni de Simone, Heinz Drexel, Michele Emdin, Dimitros Farmakis, Martin Halle, Stephane Heymans, Tiny Jaarsma, Ewa Jankowska, Mitja Lainscak, Carolyn S. P. Lam, Maja-Lisa Lochen, Yuri Lopatin, Aldo Maggioni, Benedetta Matrone, Marco Metra, Katharine Noonan, Ileana Pina, Eva Prescott, Giuseppe Rosano, Petar M. Seferovic, Karen Sliwa, Simon Stewart, Alicia Uijl, Ilonca Vaartjes, Roel Vermeulen, W. M. Monique Verschuren, Maurizio Volterrani, Stephan von Haehling, Arno Hoes
Summary: This article discusses the growing epidemic of heart failure and the importance of prevention in reducing hospital readmission rates and its clinical and economic burden. It aims to provide evidence-based information and effective preventive measures. By analyzing risk factors and population attributable risks in different continents, potential opportunities for prevention and strategies are identified. The article also lists potential interventions that have been shown to be effective in preventing heart failure.
EUROPEAN JOURNAL OF HEART FAILURE
(2022)
Review
Biochemistry & Molecular Biology
Laia Gifre-Renom, Margo Daems, Aernout Luttun, Elizabeth A. V. Jones
Summary: Endothelial cells in the body exhibit heterogeneity, which is closely linked to the specific functions of organs and tissues. Understanding the different phenotypes and diversity of endothelial cells is crucial for the development of specialized tissue engineering and vascular repair approaches. However, there is still a lack of knowledge on how tissue-specific biomechanical factors determine organ-specific phenotypes.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Cardiac & Cardiovascular Systems
Job A. J. Verdonschot, JoAo Pedro Ferreira, Anne Pizard, Pierpaolo Pellicori, Hans-Peter Brunner La Rocca, Andrew L. Clark, Franco Cosmi, Joe Cuthbert, Nicolas Girerd, Olivia J. Waring, Michiel H. T. M. Henkens, Beatrice Mariottoni, Johannes Petutschnigg, Patrick Rossignol, Mark R. Hazebroek, John G. F. Cleland, Faiez Zannad, Stephane R. B. Heymans
Summary: This study aimed to evaluate the effects of spironolactone and the characteristics of biomarkers associated with obesity. Proteomic analysis revealed a distinct biomarker profile in obese patients, reflecting adipogenesis and glucose intolerance. Additionally, obesity significantly modified the effect of spironolactone on systolic blood pressure.
JOURNAL OF CARDIAC FAILURE
(2022)
Review
Endocrinology & Metabolism
Maud van Dinther, Paulien H. M. Voorter, Jacobus F. A. Jansen, Elizabeth A. Jones, Robert J. van Oostenbrugge, Julie Staals, Walter H. Backes
Summary: Cerebral microvascular rarefaction plays an important role in the early stages of microvascular related brain disorders. Research is needed to understand its underlying pathophysiological mechanisms and develop methods to measure microvascular density for early diagnosis and treatment targets. Advanced physiological MRI techniques provide promising future tools to assess pathological alterations associated with rarefaction.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
(2022)
Editorial Material
Cardiac & Cardiovascular Systems
Stephane Heymans, Leslie T. Cooper
Summary: The risk of acute myocarditis associated with COVID-19 mRNA vaccination is rare and usually resolves quickly, while the risks of hospitalization and death from COVID-19 are greater. Therefore, COVID-19 vaccination is recommended for adolescents and adults.
NATURE REVIEWS CARDIOLOGY
(2022)
Review
Cardiac & Cardiovascular Systems
Lucas Van Hoof, Peter Verbrugghe, Elizabeth A. V. Jones, Jay D. Humphrey, Stefan Janssens, Nele Famaey, Filip Rega
Summary: The Ross procedure, or pulmonary autograft, presents an intriguing mechanobiological scenario. Understanding the mechanisms of autograft remodeling is crucial in order to make the Ross procedure a more widely accepted aortic valve substitute. Protecting the autograft during the early adaptation phase is important to prevent pathological remodeling. External support in the procedure should aim to prevent dilatation while promoting remodeling. Further research is needed to determine the optimal conditions for autograft remodeling and the underlying molecular mechanisms.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Cardiac & Cardiovascular Systems
Paolo Carai, Laura Florit Gonzalez, Stijn Van Bruggen, Valerie Spalart, Daria De Giorgio, Nadeche Geuens, Kimberly Martinod, Elizabeth Anne Vincent Jones, Stephane Heymans
Summary: The study investigates the contribution of neutrophils to the progression of viral myocarditis (VM) and found that inhibiting neutrophils and neutrophil extracellular traps (NETs) in the acute phase of VM can reduce cardiac inflammation and improve the pathological phenotype.
CARDIOVASCULAR RESEARCH
(2022)
Meeting Abstract
Biochemistry & Molecular Biology
Elizabeth A. Jones, Audrey N. Riccitelli, Dale M. Cameron, Tracy L. Kress
Article
Cardiac & Cardiovascular Systems
Paolo Carai, Anna Pia Papageorgiou, Sophie Van Linthout, Sophie Deckx, Sebastiaan Velthuis, Esther Lutgens, Erwin Wijnands, Carsten Tschoepe, Christina Schmuttermaier, Julia Kzhyshkowska, Elizabeth Anne Vincent Jones, Stephane Heymans
Summary: This study reveals the immune-suppressive role of stabilin-1 in limiting myocardial damage during viral myocarditis, by regulating the recruitment of anti-inflammatory monocytes to the site of inflammation.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Margo Daems, Laurens Liesenborghs, Robbert Boudewijns, Steven J. Simmonds, Sirima Kraisin, Jore Van Wauwe, Ilona Cuijpers, Jana Raman, Nadeche Geuens, Tina Van Buyten, Marleen Lox, Peter Verhamme, Sophie Van Linthout, Kimberly Martinod, Stephane Heymans, Carsten Tschoepe, Johan Neyts, Elizabeth A. Jones
Summary: COVID-19 patients who have recovered may experience cardiac dysfunction, even with mild infections. This study used a hamster model to investigate the cardiac effects of SARS-CoV-2 infection and found that recovered hamsters showed diastolic dysfunction, increased cardiomyocyte size, cardiac edema, and microvascular cardiac ischemia. The study also revealed that SARS-CoV-2 infection inhibited the translocation of HIF1 alpha, which could contribute to an exaggerated response upon infection.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Meeting Abstract
Cardiac & Cardiovascular Systems
Steven Simmonds, Ilona Cuijpers, Paolo Carai, Liene Vertommen, Nadeche Geuens, Aernout Lutens, Christer Betsholts, Stephane Heymans, Elizabeth Jones
Meeting Abstract
Cardiac & Cardiovascular Systems
Steven Simmonds, Jana Raman, Nadeche Geuens, Ilona Cuijpers, Stephane Heymans, Elizabeth Jones
Meeting Abstract
Cell & Tissue Engineering
Elizabeth A. V. Jones, Ashkan Tabibian, Siavash Ghaffari, Diego A. Vargas, Hans Van Oosterwyck, Richard Leask
TISSUE ENGINEERING PART A
(2022)